Mouse Hematopoietic Stem Cell Modification and Labelling by Transduction and Tracking Posttransplantation.

Mouse Hematopoietic Stem Cell Modification and Labelling by Transduction and Tracking Posttransplantation. Methods Mol Biol. 2019;1940:129-142 Authors: Cao B, Li S, Pritchard C, Williams B, Nilsson SK Abstract The tracking of the hematopoietic potential of genetically manipulated fluorescent hematopoietic stem cells (HSC) in the bone marrow (BM) allows the assessment of regulatory processes involved in the re-establishment of hematopoiesis posttransplant. Herein, we describe the means to assess the consequence of expressing specific genes in HSC on their engraftment potential posttransplant. PMID: 30788822 [PubMed - indexed for MEDLINE]
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research

Related Links:

This study provides valuable experimental evidence for clinical MM therapy. PMID: 31538911 [PubMed - as supplied by publisher]
Source: Bosnian Journal of Basic Medical Sciences - Category: General Medicine Tags: Bosn J Basic Med Sci Source Type: research
Conclusions: Tacrolimus therapeutic drug monitoring improved treatment outcomes of Chinese alloHSCT recipients. Cv measurements during weeks 3–4 and C0 or C2 measurements during weeks 5–6 better predicted aGVHD (I–IV) than the concentrations measured at other time points during the first 6 weeks after alloHSCT.
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Publication date: Available online 2 August 2019Source: BurnsAuthor(s): Jae Hyek Choi, Corina Necsoiu, Daniel Wendorff, Bryan Jordan, Alexander Dixon, Teryn R. Roberts, Brendan M. Beely, Leopoldo C. Cancio, Andriy I. BatchinskyAbstractBackgroundWe investigated effects of mesenchymal stem cells (MSC) or low-flow extracorporeal life support (ECLS) as forms of adjunct treatment for acute respiratory distress syndrome (ARDS) due to smoke inhalation injury (SII) and 40% TBSA burns by assessing their effects on histological injury scores. We hypothesized that adjunct treatments decrease histological end-organ damage.MethodsAnest...
Source: Burns - Category: Dermatology Source Type: research
Conclusions: Shengjing capsules may be a promising therapeutic medicine for NOA. The underlying mechanisms might involve activating SSCs by upregulating the integrin α6/β1 expression via the PI3K/AKT pathway. PMID: 31534468 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Contributors : Jifan Hu ; Yichen WangSeries Type : OtherOrganism : Mus musculus“chromatin-lncRNA in situ reverse transcription trap sequencing” (CRIST-Seq) approach was used to profile the lncRNA interactome in the promoter of stem cell core factors Oct4
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Other Mus musculus Source Type: research
Conclusion: 5-FU enriches the CSCs in lung adenocarcinoma cells via increasing Fbxw7 and decreasing Skp2 expression, followed by downregulation of c-myc and upregulation of p27, which switches cells to quiescence. PMID: 31534970 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Dihydroartemisinin Promotes the Osteogenesis of Human Mesenchymal Stem Cells via the ERK and Wnt/β-Catenin Signaling Pathways. Biomed Res Int. 2019;2019:3456719 Authors: Ni L, Kuang Z, Gong Z, Xue D, Zheng Q Abstract Dihydroartemisinin (DHA), which is considered to be one of the active compounds within Artemisia annua, has extensively been used in recent years as the most effective drug against malaria, having many biological functions including anticancer, antifungal, and immunomodulatory activities. However, DHA plays a role in the regulation of the proliferation and human mesenchymal stem cell...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
FLT3-ITD mutated AML is rarely cured with chemotherapy alone [1]. Current approaches incorporate allogeneic hematopoietic stem cell transplant (HSCT) in first remission for those patients who have a suitable donor and are medically qualified for transplantation [2]. Specific targeting of the oncogenic FLT3-ITD receptor to maintain remission before and after HSCT represents one avenue yet to be prospectively evaluated to improve this poor prognosis subset. Early in the post transplant period may be a unique setting to enhance the activity of targeted agents.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Medical treatment remains the mainstay of perianal disease management for CD; however, aggressive surgical management should be considered for severe or recurrent disease. In all cases of perianal CD, medical and surgical treatments should be used in tandem by a multidisciplinary team. Significant development has been made in the treatment of Crohn's-related fistulas, particularly minimally invasive options with recent clinical trials showing success with mesenchymal stem cell applications. Inevitably, some patients with severe refractory disease may require fecal diversion or proctectomy. When considering reversal of a di...
Source: Surgical Clinics of North America - Category: Surgery Authors: Source Type: research
Conference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
More News: Genetics | Molecular Biology | Stem Cell Therapy | Stem Cells